Roche lymphoma drug drives high remission rate, longer survival: study Ruby Khatun Khatun12 Dec 2017 10:00 AM ISTAn experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced,...
Novartis CAR-T therapy leads to durable response in lymphoma study Ruby Khatun Khatun11 Dec 2017 10:45 AM ISTPatients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy...